AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Biliverdin reductase A

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P53004

UPID:

BIEA_HUMAN

Alternative names:

Biliverdin-IX alpha-reductase

Alternative UPACC:

P53004; A8K747; O95019; Q86UX0; Q96QL4; Q9BRW8

Background:

Biliverdin reductase A, also known as Biliverdin-IX alpha-reductase, plays a pivotal role in the heme degradation pathway. It catalyzes the conversion of biliverdin IX alpha to bilirubin, utilizing NADH or NADPH as cofactors. This enzyme's activity is crucial for maintaining the balance between biliverdin and bilirubin levels in the body, with preferences for NADH in acidic conditions and NADPH in alkaline.

Therapeutic significance:

Hyperbiliverdinemia, characterized by green discoloration of the skin and bodily fluids, is linked to mutations affecting Biliverdin reductase A. Understanding the role of Biliverdin reductase A could open doors to potential therapeutic strategies for treating this condition and related disorders of bilirubin metabolism.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.